Researchers presented findings on the comparison of corneal epitheliotrophic factors in autologous platelet-rich plasma (APRP) and autologous serum (AS) eye drops for treating moderate-to-severe dry eye disease. The study highlighted the concentrations of key growth factors in both biological tear substitutes and their potential for tailored ophthalmic treatment, which demonstrated significant differences in growth factor concentrations between APRP and AS. The results have implications for ocular surface regeneration and treatment preferences.

Source: Ophthalmology and Therapy